Thomas Smith

“First, from a compliance perspective, can you just remind us, is there any protocol or counseling that's built into the study for patients that are experiencing weight gain or edema to help them manage this and stay on the study?”

“On the Phase 3 Performa study, appreciate the comments on the regional targeting for the trial sites. I just wanted to ask about your sense of the competitive landscape for mass trials, since there are a number of competing Phase III programs at various stages of enrollment.”

“Also, too, on the Quartropin Cal launch, if I may, are there any differences you're seeing in payer mix between these podiatrists and primary care settings versus the base business specialties?”

“I was just wondering if you could elaborate a bit on your thoughts regarding the recent FDA approval for T-Zeal in the Stage 3 T1D population, and specifically wondering how you think this potentially impacts the regulatory bar for success from the Safeguard program and how you're thinking about the potential…”

“On the 14.02 difficult-to-treat RA program, I just wanted to clarify how you're approaching the disclosure in the second half of the year. Should we expect to see the Part 2 randomized withdrawal data prior to your meeting with FDA?”